Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Bulevirtide plus pegylated interferon shows promise for hard-to-treat coinfection.
Highlights from the 2019 International Liver Congress hosted by the European Association for the Study of the Liver.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
The World Health Organization has set various benchmarks for nations to hit in controlling their epidemics by 2030.
The nation has provided unrestricted access to hepatitis C treatment since 2016.
These drugs are approved to treat all six major genotypes of hepatitis C.
Fecal microbiota transplantation can help reverse brain impairment in people with liver failure.
Given to those with polycystic kidney and liver diseases, the injectable drug reduced the volume of swollen livers.
Among HIV-positive people, mortality related to hepatitis B and C is falling but deaths due to NAFLD are rising.
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
Among study participants, having such a rare genetic disease was associated with numerous health attacks.
Among those with primary biliary cholangitis, the investigational drug reduced alkaline phosphatase levels.
This is according to two studies of real-world use of the hepatitis C regimen.
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
This from a real-world analysis of people treated for hep C in the United States.
In a small ongoing study, the treatment showed an anti-cholestatic effect.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.